Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo.

Zeng X, Sachdev D, Zhang H, Gaillard-Kelly M, Yee D.

Clin Cancer Res. 2009 Apr 15;15(8):2840-9. doi: 10.1158/1078-0432.CCR-08-1401. Epub 2009 Apr 7.

2.

Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor.

Zeng X, Zhang H, Oh A, Zhang Y, Yee D.

Breast Cancer Res Treat. 2012 May;133(1):117-26. doi: 10.1007/s10549-011-1713-x. Epub 2011 Aug 18.

3.

The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival.

Sachdev D, Zhang X, Matise I, Gaillard-Kelly M, Yee D.

Oncogene. 2010 Jan 14;29(2):251-62. doi: 10.1038/onc.2009.316. Epub 2009 Oct 19.

4.
5.

Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.

Martins AS, Mackintosh C, Martín DH, Campos M, Hernández T, Ordóñez JL, de Alava E.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3532-40.

7.

Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma.

Geoerger B, Brasme JF, Daudigeos-Dubus E, Opolon P, Venot C, Debussche L, Vrignaud P, Vassal G.

Eur J Cancer. 2010 Dec;46(18):3251-62. doi: 10.1016/j.ejca.2010.06.005. Epub 2010 Jun 28.

PMID:
20591650
8.

Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.

Amaral AT, Garofalo C, Frapolli R, Manara MC, Mancarella C, Uboldi S, Di Giandomenico S, Ordóñez JL, Sevillano V, Malaguarnera R, Picci P, Hassan AB, De Alava E, D'Incalci M, Scotlandi K.

Clin Cancer Res. 2015 Mar 15;21(6):1373-82. doi: 10.1158/1078-0432.CCR-14-1688. Epub 2015 Jan 21.

9.

Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines.

Chakraborty AK, Welsh A, Digiovanna MP.

Breast Cancer Res Treat. 2010 Apr;120(2):327-35. doi: 10.1007/s10549-009-0382-5. Epub 2009 Apr 1.

PMID:
19337828
10.

In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib.

Chakraborty AK, Zerillo C, DiGiovanna MP.

Breast Cancer Res Treat. 2015 Aug;152(3):533-44. doi: 10.1007/s10549-015-3504-2. Epub 2015 Jul 21.

PMID:
26195122
11.

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

Carboni JM, Wittman M, Yang Z, Lee F, Greer A, Hurlburt W, Hillerman S, Cao C, Cantor GH, Dell-John J, Chen C, Discenza L, Menard K, Li A, Trainor G, Vyas D, Kramer R, Attar RM, Gottardis MM.

Mol Cancer Ther. 2009 Dec;8(12):3341-9. doi: 10.1158/1535-7163.MCT-09-0499.

12.

Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment.

Fagan DH, Uselman RR, Sachdev D, Yee D.

Cancer Res. 2012 Jul 1;72(13):3372-80. doi: 10.1158/0008-5472.CAN-12-0684. Epub 2012 May 9.

14.

Epitope-specific mechanisms of IGF1R inhibition by ganitumab.

Calzone FJ, Cajulis E, Chung YA, Tsai MM, Mitchell P, Lu J, Chen C, Sun J, Radinsky R, Kendall R, Beltran PJ.

PLoS One. 2013;8(2):e55135. doi: 10.1371/journal.pone.0055135. Epub 2013 Feb 1.

15.

Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody.

Kim JG, Kang MJ, Yoon YK, Kim HP, Park J, Song SH, Han SW, Park JW, Kang GH, Kang KW, Oh DY, Im SA, Bang YJ, Yi EC, Kim TY.

PLoS One. 2012;7(3):e33322. doi: 10.1371/journal.pone.0033322. Epub 2012 Mar 16.

16.

A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells.

Sachdev D, Hartell JS, Lee AV, Zhang X, Yee D.

J Biol Chem. 2004 Feb 6;279(6):5017-24. Epub 2003 Nov 13.

17.

Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor.

Vincent EE, Elder DJ, Curwen J, Kilgour E, Hers I, Tavaré JM.

PLoS One. 2013 Jun 24;8(6):e66963. doi: 10.1371/journal.pone.0066963. Print 2013.

18.

An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.

Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blättler WA, Chittenden T, Singh R.

Cancer Res. 2003 Aug 15;63(16):5073-83.

19.

Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.

Beltran PJ, Chung YA, Moody G, Mitchell P, Cajulis E, Vonderfecht S, Kendall R, Radinsky R, Calzone FJ.

J Pharmacol Exp Ther. 2011 Jun;337(3):644-54. doi: 10.1124/jpet.110.178400. Epub 2011 Mar 8.

20.

Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.

Browne BC, Eustace AJ, Kennedy S, O'Brien NA, Pedersen K, McDermott MS, Larkin A, Ballot J, Mahgoub T, Sclafani F, Madden S, Kennedy J, Duffy MJ, Crown J, O'Donovan N.

Breast Cancer Res Treat. 2012 Dec;136(3):717-27. doi: 10.1007/s10549-012-2260-9. Epub 2012 Nov 2. Erratum in: Breast Cancer Res Treat. 2014 Dec;148(3):697.

PMID:
23117852

Supplemental Content

Support Center